Vol 93, No 11 (2022)
Research paper
Published online: 2022-01-05

open access

Page views 4473
Article views/downloads 723
Get Citation

Connect on Social Media

Connect on Social Media

A survey of knowledge, attitudes and awareness of the HPV and HPV vaccine among obstetricians and gynecologists across Poland

Dominika Trojnarska1, Rafal Baran2, Dorota Babczyk2, Robert Jach3
Pubmed: 35072233
Ginekol Pol 2022;93(11):872-880.


Objectives: The objective of this study was to assess general knowledge regarding human papillomavirus (HPV)
and the attitude to primary prevention in form of HPV vaccination (HPVv) among Polish obstetricians and gynecologists (OBGYNs). In addition, we wanted to study the willingness of physicians to promote the HPVv among patients, based on their general attitude to vaccinations as well as HPV-related knowledge. The gynecologists were also asked to assess their patients’ awareness of HPV infection.

Material and methods: A questionnaire consisting of 25 questions was used to collect the data and with support of the Polish Society of Gynecologists and Obstetricians (PTGiP) and the Polish Society of Colposcopy and Cervical Pathology (PTKiPSM) sent via their mailing lists to all members and beyond. The total amount of 213 fully filled questionnaires were gathered and analyzed using descriptive statistics.

Results: Most of the surveyed OBGYNs showed a good knowledge of HPV and HPVv. They were able to correctly identify the high-risk oncogenic HPV types (hrHPV) and admitted to using HPV genotyping in their daily practice and actively promoting HPVv, being in majority supporters of mandatory vaccinations in general. Almost 90% confirmed the importance of informing patients about sexually transmitted diseases (STDs). On the other hand, there was a group of OBGYNs with clearly insufficient knowledge about the HPV and its prevention.

Conclusions: General knowledge of Polish physicians about HPV is good, independent of gender and age. The acceptance of all vaccines is high, but the low availability of the HPV vaccines seems to be the biggest problem stopping patients from getting them.

Article available in PDF format

View PDF Download PDF file


  1. Li Ni, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128(4): 927–935.
  2. World Health Organization. Electronic address: sageexecsec@who.int. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017; 35(43): 5753–5755.
  3. ECIS - European Cancer Information System. © European Union, 2021. https://ecis.jrc.ec.europa.eu (12.11.2021).
  4. Bonanni P, Faivre P, Lopalco PL, et al. The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018-2019). Expert Rev Vaccines. 2020; 19(11): 1073–1083.
  5. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 16(1): 1–17.
  6. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005; 18(6): 391–398.
  7. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005; 37(6): 502–510.
  8. Smolarczyk K, Pieta W, Majewski S. Assessment of the State of Knowledge about HPV Infection and HPV Vaccination among Polish Resident Doctors. Int J Environ Res Public Health. 2021; 18(2).
  9. Bergman H, Buckley BS, Villanueva G, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019; 2019(11).
  10. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016; 65(49): 1405–1408.
  11. DaCarla AM. Cervical Cancer Today: Survey of ob/gyn behaviors and attitudes. Contemporary OB/GYN. 2020; 65(8).
  12. Jach R, Mazurec M, Trzeszcz M, et al. Cervical cancer screening in Poland in current SARS-CoV-2 pandemic: Interim guidelines of the Polish Society of Gynecologists and Obstetricians and the Polish Society of Colposcopy and Cervical Pathophysiology - a summary January 2021. Ginekol Pol. 2021; 92(2): 165–173.
  13. Duval B, Gilca V, McNeil S, et al. Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. Vaccine. 2007; 25(45): 7841–7847.
  14. Aldrich T, Becker D, García SG, et al. Mexican physicians' knowledge and attitudes about the human papillomavirus and cervical cancer: a national survey. Sex Transm Infect. 2005; 81(2): 135–141.
  15. Dinh TA, Rosenthal SL, Doan ED, et al. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health. 2007; 40(6): 559–563.
  16. Cipriano JJ, Scoloveno R, Kelly A. Increasing Parental Knowledge Related to the Human Papillomavirus (HPV) Vaccine. J Pediatr Health Care. 2018; 32(1): 29–35.
  17. Marlow LAV, Zimet GD, McCaffery KJ, et al. Knowledge of human papillomavirus (HPV) and HPV vaccination: an international comparison. Vaccine. 2013; 31(5): 763–769.
  18. McBride KR, Singh S. Predictors of Adults' Knowledge and Awareness of HPV, HPV-Associated Cancers, and the HPV Vaccine: Implications for Health Education. Health Educ Behav. 2018; 45(1): 68–76.
  19. Wiesenfeld HC, Dennard-Hall K, Cook RL, et al. Knowledge about sexually transmitted diseases in women among primary care physicians. Sex Transm Dis. 2005; 32(11): 649–653.
  20. The elements of a strong immunization programme – and why we need to invest in them [Internet]. WHO Regional Office for Europe; 2015. https://www.euro.who.int/__data/assets/pdf_file/0008/281528/Elements-of-a-strong-imm-prgm.pdf.
  21. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health. 2005; 37(6 Suppl): S17–S23.
  22. Pitini E, Baccolini V, Rosso A, et al. How Public Health Professionals View Mandatory Vaccination in Italy-A Cross-Sectional Survey. Vaccines (Basel). 2021; 9(6).
  23. Quattrone F, Canale A, Filippetti E, et al. Safety of HPV vaccines in the age of nonavalent vaccination. Minerva Pediatr. 2018; 70(1): 59–66.
  24. Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018; 36(32 Pt A): 4761–4767.
  25. Berkowitz Z, Malone M, Rodriguez J, et al. Providers' beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: Findings from a provider survey, 2012. Prev Med. 2015; 81: 405–411.
  26. Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics. 2010; 126(3): 425–433.
  27. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016; 16(10): 1154–1168.
  28. van de Laar RLO, Hofhuis W, Duijnhoven RG, et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. BMC Cancer. 2020; 20(1): 539.
  29. Sherman SM, Cohen CR, Denison HJ, et al. A survey of knowledge, attitudes and awareness of the human papillomavirus among healthcare professionals across the UK. Eur J Public Health. 2020; 30(1): 10–16.